UNIGE document Scientific Article
previous document  unige:7355  next document
add to browser collection
Title

Delavirdine in combination with zidovudine in treatment of human immunodeficiency virus type 1-infected patients: evaluation of efficacy and emergence of viral resistance in a randomized, comparative phase III trial. The M/3331/0013B Study Group

Authors
Joly, V.
Moroni, M.
Concia, Ercole
Lazzarin, A.
Jost, J.
Chiodo, F.
Bentwich, Z.
show hidden authors show all authors [1 - 16]
Published in Antimicrobial Agents and Chemotherapy. 2000, vol. 44, no. 11, p. 3155-3157
Abstract We compared the activity of delavirdine (DLV) plus zidovudine (AZT) (n = 300) with that of AZT (n = 297) against human immunodeficiency virus type 1 in a randomized, double-blind, placebo-controlled trial. DLV exerted a transient antiviral effect, and mutations for resistance to DLV were found in more than 90% of subjects at week 12. The K103N mutation, which confers nonnucleoside reverse transcriptase inhibitor cross-resistance, was found in 85% of the patients.
Keywords Anti-HIV Agents/ therapeutic useDelavirdine/ therapeutic useDouble-Blind MethodDrug Resistance, MicrobialDrug Therapy, CombinationHIV Infections/ drug therapyHIV Reverse Transcriptase/geneticsHIV-1/drug effects/geneticsHumansTreatment OutcomeZidovudine/therapeutic use
Identifiers
PMID: 11036040
Full text
Structures
Citation
(ISO format)
JOLY, V. et al. Delavirdine in combination with zidovudine in treatment of human immunodeficiency virus type 1-infected patients: evaluation of efficacy and emergence of viral resistance in a randomized, comparative phase III trial. The M/3331/0013B Study Group. In: Antimicrobial Agents and Chemotherapy, 2000, vol. 44, n° 11, p. 3155-3157. https://archive-ouverte.unige.ch/unige:7355

167 hits

0 download

Update

Deposited on : 2010-06-21

Export document
Format :
Citation style :